BioMérieux to acquire SpinChip

Financials Growth Revenue Business Social

BioMérieux announced that it has entered an agreement to acquire diagnostics firm SpinChip.

Under the terms of the agreement, BioMérieux will acquire full ownership of SpinChip for a total of 138 million euros ($141.8 million), the company said in a statement. The cash out will amount to approximately 111 million euros ($114 million), as BioMérieux has held 20% of the shares of the Norwegian firm since March 2024.

BioMérieux expects to complete the acquisition shortly.

The acquisition will strengthen BioMérieux’s position in the point-of-care market, the company said. SpinChip’s offerings include a benchtop immunoassay diagnostics platform, suited to near-patient testing, which provides results from whole-blood samples within 10 minutes with high sensitivity.

SpinChip is currently developing tests for common acute-care indications, including myocardial infarction, a leading cause of mortality globally. The first such assay, known as hs-TnI, has been validated in a retrospective clinical study and is currently being assessed in a multicenter clinical trial.

SpinChip expects to apply for CE marking for the assay under the European Union's In Vitro Diagnostic Regulation (IVDR) before the end of 2025, the firms noted, with the first product launch expected in 2026.

Page 1 of 13
Next Page